Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) Enterprise Value (2018 - 2025)

TransMedics has reported Enterprise Value over the past 8 years, most recently at -$488.4 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$488.4 million for Q4 2025, down 45.07% from a year ago — trailing twelve months through Dec 2025 was -$488.4 million (down 45.07% YoY), and the annual figure for FY2025 was -$488.4 million, down 45.07%.
  • Enterprise Value for Q4 2025 was -$488.4 million at TransMedics, down from -$466.2 million in the prior quarter.
  • Over the last five years, Enterprise Value for TMDX hit a ceiling of -$58.1 million in Q2 2022 and a floor of -$582.2 million in Q2 2023.
  • Median Enterprise Value over the past 5 years was -$330.1 million (2024), compared with a mean of -$284.8 million.
  • Biggest five-year swings in Enterprise Value: surged 48.26% in 2022 and later tumbled 902.36% in 2023.
  • TransMedics' Enterprise Value stood at -$92.5 million in 2021, then plummeted by 117.61% to -$201.2 million in 2022, then crashed by 96.25% to -$394.8 million in 2023, then increased by 14.73% to -$336.6 million in 2024, then plummeted by 45.07% to -$488.4 million in 2025.
  • The last three reported values for Enterprise Value were -$488.4 million (Q4 2025), -$466.2 million (Q3 2025), and -$400.6 million (Q2 2025) per Business Quant data.